Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT125B in relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma
NCT05487495Phase 1Withdrawn
- Sponsor
- Beijing Boren Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CT125B in acute lymphoblastic leukemia (ALL) and lymphoma, sponsored by Beijing Boren Hospital. Primary endpoint: Incidence and type of dose-limiting toxicity at 21 days. Planned start Aug 2022; status: withdrawn.
02
Drugs
CT125B
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoma
Beyond the preview
Go deeper on NCT05487495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487495.